Nervous System & Special Senses

Restless legs syndrome: workup and management

Clinical Overview and When to Suspect Restless Legs Syndrome

— Urge to move the legs, usually with uncomfortable sensations ("creepy-crawly," "electric," "pulling")

— Rest worsens symptoms (sitting, lying down)

— Gets better with movement (walking, stretching)

— Evening/night predominance (circadian pattern)

— Not solely explained by another condition (leg cramps, positional discomfort, arthritis, neuropathy)

— Primary (idiopathic): often familial, earlier onset (<45 yrs), slower progression

— Secondary: iron deficiency, ESRD/dialysis, pregnancy (especially 3rd trimester), neuropathy, certain medications

— Chronic insomnia complaints, particularly sleep-onset insomnia

— Daytime fatigue with reports of nocturnal leg discomfort

— Bed partner reports of leg kicking or periodic limb movements of sleep (PLMS)

— Patients on SSRIs/SNRIs, antihistamines, antiemetics (metoclopramide), or antipsychotics — these unmask or worsen RLS

Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a common sensorimotor disorder affecting 5–10% of US adults and ~2–3% with clinically significant symptoms warranting treatment.

Defined by the URGE criteria (all five required):

Pathophysiology: central iron deficiency in substantia nigra and dopaminergic dysregulation; genetic risk loci (BTBD9, MEIS1) confer familial predisposition.

Two clinical phenotypes:

When to suspect in family medicine clinic:

Board pearl: RLS is a clinical diagnosis — no labs or polysomnography needed for diagnosis itself. However, every new RLS patient gets a ferritin because iron repletion can be curative.

Severity is graded with the International RLS Study Group (IRLSSG) Rating Scale; ≥15 typically considered moderate-severe and prompts pharmacotherapy.

Step 3 framing: distinguish bothersome occasional symptoms (lifestyle modification, withdraw offending drugs) from chronic-persistent RLS (≥2 episodes/week with significant distress) requiring directed therapy.

Presentation Patterns and Key History

— Timing: symptoms onset evening/night, peak 11pm–3am; daytime symptoms suggest severe disease or augmentation

— Quality: sensations are often hard to describe — "deep, achy, jittery, electric" — but not painful in the neuropathic burning sense

— Bilateral vs unilateral: usually bilateral; strictly unilateral persistent symptoms should raise suspicion for radiculopathy or vascular cause

— Movement response: relief is immediate with walking — a near-pathognomonic feature

— Family history: present in ~50% of primary cases; ask explicitly

— Iron deficiency: heavy menses, GI bleeding, vegetarian diet, recent pregnancy, frequent blood donation

— CKD/ESRD on dialysis (up to 30% have RLS)

— Pregnancy (especially 3rd trimester; usually remits postpartum)

— Peripheral neuropathy (diabetes, B12 deficiency)

— Medication review: SSRIs, SNRIs, TCAs, mirtazapine, diphenhydramine, dopamine antagonists (metoclopramide, prochlorperazine, antipsychotics)

— Substances: caffeine, alcohol, nicotine — all worsen symptoms

— Sleep latency, total sleep time, daytime sleepiness, work/driving impairment, mood symptoms (RLS doubles depression risk)

Classic stem: middle-aged woman with months of difficulty falling asleep, describes "ants crawling" in calves that improves only when she gets out of bed to walk. Partner notes she kicks during sleep.

Targeted history elements:

Screen for secondary/exacerbating contributors:

Functional impact — quantify for severity:

Key distinction: RLS vs nocturnal leg cramps — cramps are sudden, painful, focal (calf), with palpable muscle knot, not relieved by walking the way RLS is, and lack the urge-to-move quality.

Step 3 management: Before prescribing, always ask the patient to list every OTC sleep aid, allergy med, and antiemetic — diphenhydramine in PM cold preparations is a frequent unrecognized trigger that resolves with discontinuation alone.

Physical Exam Findings and Functional Assessment

— Neurologic exam: strength, deep tendon reflexes (loss of ankle jerks suggests neuropathy), vibration and monofilament testing on feet (diabetic/B12 neuropathy), Romberg

— Vascular exam: dorsalis pedis and posterior tibial pulses, ankle-brachial index if claudication suspected, skin changes of chronic venous insufficiency (hyperpigmentation, varicosities, edema)

— Musculoskeletal: straight leg raise (radiculopathy), hip and knee ROM, palpation for tenderness

— Skin: pallor of conjunctivae/palms (anemia); spoon nails (severe iron deficiency)

— Thyroid: goiter, reflexes (hypothyroidism can mimic fatigue picture)

— Epworth Sleepiness Scale for daytime sleepiness burden

— IRLSSG severity scale (10 items, 0–40) to grade severity and track response

— Sleep diary for 1–2 weeks: sleep latency, awakenings, total sleep time

— Screen depression (PHQ-9) and anxiety (GAD-7) — bidirectional comorbidity

— ABI <0.9 suggests PAD with claudication; PAD pain is exertional and relieved by rest (opposite of RLS)

RLS exam is characteristically normal — this is part of the diagnostic frame. A normal neurologic and vascular exam supports primary RLS; abnormalities push you toward a mimic.

Required exam components in initial evaluation:

Functional and sleep assessment in clinic:

Bed partner observation is invaluable: kicking, periodic leg jerks every 20–40 seconds during sleep suggests PLMS, present in ~80% of RLS patients but not required for diagnosis.

Hemodynamic assessment is relevant only if a vascular mimic is suspected:

Board pearl: A patient with abnormal exam findings — sensory deficits, absent reflexes, atrophy, foot drop, or diminished pulses — likely has a secondary cause or RLS mimic, not idiopathic RLS. Pursue the abnormality.

Step 3 management: Document BMI, BP, and gait — these set baseline for medication safety (dopamine agonists cause orthostasis; α2δ ligands cause weight gain and ataxia in elderly).

Diagnostic Workup — Initial Labs

— Ferritin (the single most important test) plus transferrin saturation (TSAT), iron, TIBC, CBC

— BMP with creatinine and eGFR (uremic RLS)

— Fasting glucose or HbA1c (diabetic neuropathy as mimic/contributor)

— TSH (hypothyroidism contributes to fatigue picture)

— Vitamin B12 and folate (neuropathy mimic)

— Magnesium in patients with cramps or on PPIs/diuretics

— Ferritin <75 ng/mL (or TSAT <20%) → iron supplementation is indicated, even if Hgb is normal

— Goal ferritin >100 ng/mL and TSAT >20% for symptom control

— Ferritin is an acute phase reactant — interpret with CRP if inflammation suspected

— Oral: ferrous sulfate 325 mg + vitamin C every other day (better absorption than daily dosing per recent evidence), taken on empty stomach; recheck ferritin in 3 months

— IV iron indicated if: ferritin <100 with severe symptoms, oral intolerance, malabsorption, ongoing blood loss, or need for rapid response. Ferric carboxymaltose is first-line IV agent for RLS

— HbA1c, fasting lipids in patients with neuropathic features

— SPEP if unexplained neuropathy in older adult

— Pregnancy test before initiating pharmacotherapy in reproductive-age women

RLS is a clinical diagnosis, but every patient gets a focused lab panel to identify treatable contributors and exclude mimics.

Mandatory initial labs in all suspected RLS:

Ferritin interpretation in RLS — critically different from anemia thresholds:

Iron repletion strategy:

Additional labs case-by-case:

Board pearl: A normal Hgb does not exclude clinically meaningful iron deficiency in RLS. The brain may be iron-deficient with adequate peripheral iron stores. Ferritin <75 = treat with iron.

Step 3 management: After iron repletion, 30–50% of patients with low ferritin have significant symptom improvement, often enough to defer or reduce pharmacotherapy — making ferritin both diagnostic and therapeutic.

Diagnostic Workup — Advanced or Confirmatory Studies

— Atypical features (daytime-only symptoms, unilateral, painful)

— Suspected comorbid obstructive sleep apnea (snoring, BMI elevated, witnessed apneas)

— Treatment failure despite optimized therapy

— Suspected PLMD (periodic limb movement disorder) without RLS criteria

— Documents PLMS index >15/hr (supportive but not diagnostic for RLS)

— Brain MRI with iron-sensitive sequences (research): shows reduced substantia nigra iron in primary RLS — not used clinically

— CSF ferritin: decreased in RLS — research only

Most patients with classic URGE-criteria RLS need no advanced studies — overuse of polysomnography is a low-value testing pitfall on boards.

Polysomnography (PSG) — limited indications:

Suggested Immobilization Test (SIT): patient sits with legs extended for 1 hr in evening; objective measure of leg movements and subjective discomfort — used in research and select tertiary clinics.

Electromyography/Nerve conduction studies (EMG/NCS): indicated when neuropathy is suggested by exam (sensory loss, absent reflexes) — confirms peripheral neuropathy as a contributor or mimic. RLS itself shows normal EMG/NCS.

MRI lumbar spine: only if radicular pattern (dermatomal pain, motor weakness, positive SLR) — rules out lumbosacral radiculopathy.

Vascular studies (ABI, venous duplex): if PAD or chronic venous insufficiency suspected by exam.

Newer/specialized testing:

Documentation for diagnosis: ensure URGE criteria explicitly recorded; mimics excluded; ferritin checked.

Key distinction: PLMD vs RLS — PLMD is diagnosed by PSG showing PLMS with clinical impact in the absence of URGE criteria. RLS does not require PSG and can exist without PLMS.

Board pearl: A patient meeting all 5 URGE criteria with a normal exam and ferritin checked needs no further diagnostic testing before initiating management. Ordering PSG in this scenario is the wrong answer.

Step 3 management: If a patient on dopamine agonists develops worsening daytime/morning symptoms — this is augmentation, a clinical diagnosis, not an indication for PSG.

Risk Stratification and First-Line Management Logic

— Intermittent RLS (<2 episodes/week, mild impact): non-pharmacologic + as-needed therapy

— Chronic-persistent RLS (≥2 episodes/week with bothersome symptoms): daily pharmacotherapy

— Refractory RLS: persistent despite adequate monotherapy or augmentation on dopamine agonist

— Check and repleate ferritin to target >100 ng/mL

— Discontinue or substitute offending medications:

— SSRIs/SNRIs → consider bupropion (does not worsen and may help RLS)

— Diphenhydramine, doxylamine → eliminate

— Metoclopramide, prochlorperazine → switch to ondansetron

— Antipsychotics → discuss risk/benefit with psychiatry

— Lifestyle modifications:

— Reduce caffeine, alcohol, nicotine

— Regular moderate exercise (avoid intense exercise close to bedtime)

— Sleep hygiene: consistent schedule, cool dark room

— Counter-stimulation: hot/cold packs, massage, pneumatic compression devices, vibrating pads (FDA-cleared "Relaxis" pad)

— Carbidopa-levodopa 25/100 PRN for predictable triggers (long flights, theater) — useful but high augmentation risk if used >2–3 times/week

— Low-dose gabapentin as needed

— Benzodiazepines (clonazepam) — discouraged due to dependence, falls

— α2δ calcium channel ligands (gabapentin enacarbil, pregabalin, gabapentin) = preferred first-line

— Dopamine agonists (pramipexole, ropinirole, rotigotine) = effective but reserved due to augmentation and impulse control disorder risks

Management is tiered by frequency, severity, and reversible contributors:

Universal first steps (do these before prescribing):

Intermittent symptom strategies:

Daily therapy — choosing first-line class (current AAN/AASM 2024 guidance favors α2δ ligands):

Board pearl: The pendulum has swung — α2δ ligands are now preferred over dopamine agonists as first-line daily therapy because of unacceptable rates of augmentation (up to 7% per year on pramipexole).

Step 3 management: Ask about gambling, hypersexuality, and compulsive shopping at every dopamine agonist follow-up — informed consent for these risks is required at initiation.

Pharmacotherapy — First-Line Drug Regimens

— Gabapentin enacarbil 600 mg PO once daily at 5 PM (FDA-approved specifically for RLS); titrate to 1200 mg if needed

— Pregabalin 75–300 mg PO at bedtime (off-label but well-studied)

— Gabapentin 300–1800 mg PO 2 hr before symptom onset, divided dosing if >600 mg (saturable absorption)

— Best for: RLS with neuropathic pain, anxiety, insomnia, or history of impulse control disorder

— Side effects: sedation, dizziness, weight gain, peripheral edema, ataxia (especially elderly), suicidality warning

— Avoid in: severe renal impairment without dose reduction; history of substance use disorder (some misuse potential)

— Pramipexole 0.125 mg 2–3 hr before bedtime; titrate weekly to max 0.5 mg

— Ropinirole 0.25 mg 1–3 hr before bedtime; titrate to max 4 mg

— Rotigotine patch 1–3 mg/24 hr — useful for 24-hr symptoms or GI issues

— Side effects: augmentation (earlier onset, increased intensity, spread to arms), rebound, nausea, orthostasis, daytime sleepiness, impulse control disorders (gambling, hypersexuality, binge eating — ~17% incidence)

— Use lowest effective dose; avoid exceeding FDA-approved maxima

— Low-dose extended-release oxycodone or methadone for severe refractory disease unresponsive to α2δ ligands and dopamine agonists, or in augmentation rescue

— Requires opioid agreement, urine drug screen monitoring, PDMP check

— Benzodiazepines (falls, dependence, especially elderly)

— Carbidopa-levodopa daily (very high augmentation rate)

α2δ calcium channel ligands — preferred first line:

Dopamine agonists — second-line for most, first-line in select cases:

Opioids — for refractory RLS only:

Iron (if ferritin <75): see Chunk 4 — counts as disease-modifying therapy

Avoid/limit:

Board pearl: First-line for uncomplicated chronic RLS = gabapentin enacarbil or pregabalin. First-line for RLS with severe sleep disruption and no comorbid pain still favors α2δ; dopamine agonist only if α2δ contraindicated or ineffective.

CCS pearl: Schedule follow-up in 4–6 weeks after starting any RLS pharmacotherapy to assess response, side effects, and titrate.

Augmentation, Refractory Disease, and Advanced Pharmacology

— Earlier symptom onset (e.g., now in afternoon instead of evening)

— Increased intensity and shorter latency to symptoms after rest

— Anatomic spread (arms, trunk)

— Shorter duration of medication benefit

— Risk factors: pramipexole/ropinirole use, higher doses, lower ferritin, longer duration of therapy

— Confirm and replete iron (ferritin >100)

— Move dose earlier in the day and split dosing

— Switch to rotigotine patch (lower augmentation rate than oral agents) or cross-taper to α2δ ligand

— In severe cases: discontinue dopamine agonist entirely, bridge with low-dose opioid during washout (expect 1–2 weeks of withdrawal-related symptom worsening)

— Avoid simply increasing the dopamine agonist dose — this accelerates augmentation

— Step 1: Maximize α2δ ligand + iron repletion

— Step 2: Add or switch to dopamine agonist (rotigotine patch preferred)

— Step 3: Combination α2δ + dopamine agonist

— Step 4: Add low-dose opioid (oxycodone ER 5–10 mg, methadone 5–10 mg)

— Referral to sleep medicine or movement disorder specialist

— Ferric carboxymaltose 1000 mg IV (single dose or 750 mg × 2) — well-studied in RLS

— Indicated when ferritin <100 and oral iron failed/not tolerated

— Monitor for hypophosphatemia (notable with ferric carboxymaltose), infusion reactions

— Pneumatic compression devices, vibrating pads (Relaxis) — adjunctive

— Transcutaneous spinal direct current stimulation — experimental

— Tonic motor activation device (NTX100) — FDA-cleared peroneal nerve stimulator for medication-refractory cases

Augmentation is the most important iatrogenic complication in RLS — a paradoxical worsening from dopaminergic therapy:

Management of augmentation:

Refractory RLS algorithm:

IV iron in refractory or severe disease:

Procedural/device options:

Board pearl: A patient on pramipexole 0.5 mg whose symptoms now start at 2 PM and involve the arms — this is augmentation, not undertreatment. Do not increase the dose.

Step 3 management: Cross-taper to gabapentin enacarbil over 2–4 weeks while reducing dopamine agonist; warn patient about temporary worsening.

Special Populations — Elderly and Renal/Hepatic Impairment

— RLS prevalence increases with age; up to 10–20% in those >65

— Higher fall risk with dopamine agonists (orthostasis, daytime sleepiness) and α2δ ligands (ataxia, dizziness)

— Polypharmacy review: many elderly are on diphenhydramine (sleep aids), metoclopramide, antipsychotics — deprescribe before adding new RLS medication

— Start at the lowest dose and titrate slowly

— Avoid benzodiazepines (Beers Criteria)

— Cognitive screening before starting α2δ ligands — gabapentinoids can worsen cognition in dementia

— RLS affects 20–30% of dialysis patients — uremic toxins, iron dysregulation, secondary hyperparathyroidism contribute

— Optimize dialysis adequacy, treat anemia (epoetin) and iron deficiency aggressively

— Gabapentin and pregabalin require significant dose reduction in CKD:

— Gabapentin: CrCl 30–59 → max 700 mg/day; CrCl 15–29 → max 300 mg/day; <15 → 100 mg/day

— Pregabalin: similar tiered reduction

— Risk of myoclonus and encephalopathy if not renally dosed

— Gabapentin enacarbil — avoid in CrCl <30

— Dopamine agonists: pramipexole is renally cleared and requires dose adjustment; ropinirole hepatically metabolized — may be preferable in CKD

— Rotigotine patch — no renal adjustment needed; useful option in ESRD

— Ropinirole undergoes hepatic CYP1A2 metabolism — caution in cirrhosis; smoking induces CYP1A2 and reduces levels

— Pramipexole preferred in hepatic dysfunction (renal clearance) if renal function preserved

— α2δ ligands minimally hepatically metabolized — generally safe

Elderly considerations:

Chronic kidney disease and ESRD:

Hepatic impairment:

Board pearl: A dialysis patient with new-onset RLS — first move is iron studies and optimize dialysis/anemia management before adding pharmacotherapy. Rotigotine patch is a good first-line agent if drug therapy needed.

Step 3 management: Always recalculate eGFR before each gabapentinoid dose escalation in patients >65 — undetected AKI is a common cause of new gabapentin toxicity (sedation, myoclonus, ataxia).

Special Populations — Pregnancy and Other Subgroups

— RLS occurs in ~20% of pregnancies, peaking in the 3rd trimester; typically resolves within weeks postpartum

— Pathophysiology: estrogen, iron and folate depletion, mechanical factors

— First-line approach is non-pharmacologic:

— Iron and folate supplementation — check ferritin, target >75; iron is cornerstone

— Sleep hygiene, leg massage, warm baths, moderate exercise, compression

— Counter-stimulation devices

— Pharmacologic therapy — reserved for severe symptoms after non-drug measures:

— Low-dose clonazepam or oxycodone at lowest effective dose late in pregnancy (avoid 1st trimester) per shared decision-making

— Gabapentin — limited human data; can be considered in 2nd/3rd trimester

— Avoid dopamine agonists in pregnancy and during breastfeeding (suppress lactation)

— Reassure: pregnancy-induced RLS usually remits postpartum

— Avoid dopamine agonists (decrease prolactin → suppress lactation)

— Gabapentin transfers into breast milk but limited data suggests acceptable use

— RLS does occur in children; often misdiagnosed as ADHD or "growing pains"

— First-line: iron repletion (ferritin <50 in children warrants treatment)

— Behavioral measures, sleep hygiene, reduce caffeine (sodas)

— Pharmacotherapy reserved for severe cases; gabapentin off-label; refer to pediatric sleep specialist

— Association with ADHD — bidirectional; treat RLS, ADHD symptoms may improve

— High comorbidity with insomnia and PTSD

— Avoid SSRIs that worsen RLS — consider bupropion-based strategies

— Long immobility (post-op) and discontinuation of home meds can trigger severe RLS flares

— Continue home RLS medications perioperatively; alternative routes (rotigotine patch) for NPO patients

Pregnancy:

Breastfeeding:

Pediatrics:

Veterans/PTSD population:

Surgical/perioperative patients:

Board pearl: Pregnant woman with new RLS in 3rd trimester → check ferritin and supplement iron + folate first. Reassure remission postpartum. Avoid dopamine agonists.

Step 3 management: A child labeled "ADHD" with leg discomfort and disturbed sleep — check ferritin before escalating stimulant therapy.

Complications and Adverse Outcomes

— Chronic insomnia with prolonged sleep latency and frequent awakenings

— Mean sleep loss of 1–2 hours/night in moderate-severe RLS

— Daytime sleepiness → impaired work performance, increased motor vehicle accident risk

— 2-fold increased risk of major depression

— Elevated anxiety disorder prevalence

— Increased suicidal ideation — RLS is independently associated with suicide risk in large cohorts

— Bidirectional: depression treatments (SSRIs) often worsen RLS, creating therapeutic dilemma

— Periodic limb movements cause repeated nocturnal BP and HR surges

— Observational data link RLS to increased hypertension and possibly stroke/CAD risk, though causality debated

— Treat aggressively in patients with established cardiovascular disease

— Chronic sleep deprivation → attention deficits, memory complaints

— Some evidence of increased dementia risk in long-standing untreated RLS

— Augmentation (dopamine agonists) — see Chunk 8

— Impulse control disorders (ICDs): pathological gambling, hypersexuality, compulsive shopping, binge eating — occur in 14–17% of patients on dopamine agonists; can be devastating financially and personally

— Daytime somnolence with "sleep attacks" — driving risk on dopamine agonists

— Pretibial edema, weight gain, dizziness, falls (gabapentinoids)

— Opioid-related: constipation, dependence, sleep-disordered breathing

— Iron-related: GI upset (oral), hypophosphatemia (IV ferric carboxymaltose), rare anaphylaxis (IV)

Sleep-related morbidity:

Psychiatric comorbidity:

Cardiovascular implications:

Cognitive effects:

Treatment-related complications:

Pregnancy-related: untreated severe RLS → maternal sleep deprivation, possible association with peripartum mood disorders

Quality of life: moderate-severe RLS produces disability scores comparable to type 2 diabetes and osteoarthritis.

Board pearl: A patient on pramipexole presents with new gambling debts and marital strain — recognize impulse control disorder, discontinue or taper the dopamine agonist, and transition to an α2δ ligand.

Step 3 management: Screen for ICDs (QUIP-RS or direct questioning) at every dopamine agonist visit and document the discussion.

When to Escalate Care — Consult or Refer

— Refractory symptoms despite optimized first-line and second-line therapy

— Augmentation requiring complex medication transitions

— Suspected comorbid sleep disorder (OSA, narcolepsy) needing PSG and management

— Atypical features: unilateral, daytime predominant, painful, focal neurological signs

— Pediatric RLS requiring pharmacotherapy

— Need for opioid therapy (some institutions require specialist co-management)

— Patient on multiple medication classes with unclear strategy

— Concern for Parkinson disease — note that RLS is not a strong PD risk factor despite shared dopaminergic biology

— Suspected peripheral neuropathy needing EMG/NCS workup

— Spinal cord lesion suspected (myelopathy mimicking RLS)

— Dialysis patients with refractory RLS — optimize dialysis prescription, iron, anemia management

— Severe comorbid depression where SSRIs are unavoidable — co-manage to minimize RLS exacerbation

— Active impulse control disorder from dopamine agonists

— Recurrent iron deficiency without obvious source — needs GI workup (colonoscopy, EGD per age and risk)

— Failure to respond to IV iron repletion

— Severe acute symptom exacerbation with sleep deprivation–related psychosis

— Acute serotonin syndrome from medication interactions

— Opioid withdrawal precipitating severe RLS flare

Most RLS is managed in primary care. Indications for specialist referral or escalation:

Refer to sleep medicine or movement disorder specialist when:

Neurology referral:

Nephrology coordination:

Psychiatry:

Hematology:

Emergency department referral is rarely needed for RLS itself, but consider for:

Board pearl: RLS itself almost never requires hospitalization. If a hospitalized patient develops severe RLS, common culprits are: withholding home dopamine agonist, new metoclopramide/prochlorperazine, antipsychotics for delirium, or new SSRI.

CCS pearl: When a hospitalized RLS patient is NPO, switch oral dopamine agonist to rotigotine transdermal patch to maintain therapy and prevent withdrawal/augmentation rebound.

Key Differentials — Same-Category (Movement and Sensory)

— Repetitive stereotyped leg movements during sleep with clinical sleep disruption

— Diagnosed by PSG, requires absence of URGE criteria

— RLS patients commonly have PLMS but do not need PSG; PLMD without RLS is rarer

— Painful, sudden, focal (usually calf), palpable muscle contraction

— Relieved by stretching, not by walking

— Lasts seconds to minutes, then aching residue

— Common in elderly, pregnancy, dehydration, statins, diuretics

— Sense of inner restlessness with need to move, often whole body, not legs-specific

— Lacks circadian pattern (occurs throughout day)

— Caused by dopamine antagonists (antipsychotics, metoclopramide)

— Treatment: reduce/discontinue offending agent; propranolol, benztropine

— Single myoclonic jerk at sleep onset, not repetitive, normal phenomenon

— Continuous toe writhing with deep leg pain; associated with neuropathy or radiculopathy

— Patient can suppress; no urge, no sensory component

— Diffuse pain and fatigue; sleep disturbance is non-specific; RLS commonly comorbid

— Bilateral leg pain in evening; lacks urge to move; relieved by parental massage

— Distinguishing line: RLS in children has urge-to-move and movement-relief features

— Stereotyped motor activity in sleep, often dystonic; EEG/video PSG distinguishes

Distinguishing RLS from sleep- and movement-related mimics:

Periodic Limb Movement Disorder (PLMD):

Nocturnal leg cramps:

Akathisia:

Hypnic jerks (sleep starts):

Painful legs and moving toes syndrome:

Volitional movements/habit (jimmy legs):

Fibromyalgia:

Growing pains (pediatric):

Hypnogenic dyskinesias and nocturnal seizures:

Key distinction: Akathisia vs RLS — akathisia is drug-induced, diurnal, involves whole body, and lacks the rest-worsens/movement-relieves circadian pattern. Always review medication list when restless movement is described.

Board pearl: A patient on haloperidol for delirium develops generalized restlessness without a circadian pattern — this is akathisia, treat by reducing antipsychotic and adding propranolol or benztropine, not by starting a dopamine agonist.

Key Differentials — Other-Category Causes

— Exertional claudication, relieved by rest (opposite of RLS)

— Diminished pulses, hair loss, dependent rubor, ABI <0.9

— Workup: ABI, vascular consult

— Heaviness, aching worse with standing, improved by leg elevation

— Varicose veins, edema, hyperpigmentation, stasis dermatitis

— Treatment: compression stockings, elevation, venous procedures

— Burning, tingling, numbness; sock-glove distribution

— Constant or position-independent; does not have the urge-to-move quality

— Etiologies: diabetes, B12, alcohol, chemotherapy

— Can coexist with RLS; treat both

— Dermatomal pain, often unilateral, worsened by certain positions

— Positive straight leg raise, motor/sensory deficit

— MRI confirms; treat with PT, NSAIDs, possible epidural

— Fatigue, weight gain, constipation, hair loss; can cause myalgia and cramps

— TSH excludes

— Same URGE pattern but involving arms or trunk; rare and often suggests advanced or augmented RLS

— Stimulants, theophylline, β-agonists, withdrawal states

— Conscious, voluntary; relieved by attention to the activity, no urge

— Bilateral leg symptoms with upper motor neuron signs (hyperreflexia, Babinski), bowel/bladder changes

— MRI cord imaging

— Rigidity, bradykinesia, resting tremor; nocturnal akinesia can mimic RLS

— Treatment overlap with dopaminergic therapy can confuse the picture

Conditions that masquerade as RLS or cause leg discomfort warranting exclusion:

Peripheral arterial disease (PAD):

Chronic venous insufficiency:

Peripheral neuropathy:

Lumbosacral radiculopathy:

Hypothyroidism:

Restless arms / restless body variants of RLS:

Drug-induced restlessness:

Psychogenic/anxiety-driven leg jiggling:

Myelopathy or spinal cord disease:

Parkinson disease early symptoms:

Board pearl: PAD pain is brought on by walking and relieved by rest; RLS is brought on by rest and relieved by walking. A patient who states "I walk to get rid of it" is RLS; "I have to stop walking and rest" is PAD.

Step 3 management: When the history is ambiguous in an older patient with vascular risk factors, order an ABI before initiating RLS pharmacotherapy.

Secondary Prevention and Long-Term Plan

— Use lowest effective dose of any agent to minimize side effects and (for dopamine agonists) delay augmentation

— Drug holidays are not generally effective in RLS (unlike some chronic pain syndromes)

— Reassess need annually — some patients (especially those with corrected iron deficiency or pregnancy-related) can taper off

— Pre-emptively manage triggers: caffeine, alcohol, nicotine, offending medications

— Recheck ferritin every 6–12 months in patients with prior deficiency or on supplementation

— Maintain ferritin >100 ng/mL, TSAT >20%

— Re-evaluate for new iron loss (menses, GI bleeding) if levels drop

— Regular moderate aerobic exercise (30 min, most days) — shown to improve RLS severity

— Sleep hygiene as standing recommendation

— Limit caffeine to morning hours; minimize alcohol; tobacco cessation

— Maintain an "RLS-avoid list" in the chart: diphenhydramine, metoclopramide, prochlorperazine, sedating antihistamines, certain antipsychotics, SSRIs/SNRIs (use bupropion when feasible for depression)

— Communicate with other providers and pharmacy

— Aggressively treat comorbid OSA, depression, anxiety, neuropathy — improves RLS outcomes

— Optimize diabetes control to limit neuropathic contribution

— In CKD: optimize dialysis, anemia, and bone-mineral metabolism

RLS is a chronic condition for most patients — frame as a long-term management partnership.

Long-term medication strategy:

Iron status — ongoing surveillance:

Lifestyle prescriptions:

Medication list review at every visit:

Comorbidity management:

Vaccinations and preventive care: standard age-appropriate screening; ensure flu/pneumococcal/COVID per USPSTF and ACIP; falls prevention assessment in elderly on pharmacotherapy

Patient education materials and support: RLS Foundation, peer support groups improve adherence

Board pearl: When a patient with stable RLS on therapy is started on a new SSRI by another clinician and returns with worsening symptoms — the answer is switch antidepressant to bupropion, not escalate RLS medication.

Step 3 management: Update problem list and medication reconciliation at every visit to flag interactions; provide patient with written "medications to avoid" list.

Follow-Up, Monitoring, and Counseling

— 2–4 weeks after starting or changing pharmacotherapy: assess response, side effects, titration

— 6–8 weeks to reach therapeutic dose and reassess

— 3 months for ferritin recheck after iron repletion

— Stable patients: every 6–12 months

— Dopamine agonist patients: every 3–6 months with explicit screening for augmentation and impulse control disorders

— Opioid therapy: monthly visits, opioid agreement, PDMP check, urine drug screens, naloxone co-prescription

— IRLSSG severity score trend

— Sleep quality (sleep diary or PROMIS sleep)

— Daytime function and Epworth Sleepiness Scale

— Mood (PHQ-9, GAD-7)

— Augmentation screen (timing, intensity, anatomic spread)

— ICD screen (gambling, sexual behavior, shopping, eating)

— Weight, BP, orthostatic vitals if on dopamine agonist

— Ferritin every 6–12 months

— Renal function (especially elderly, gabapentinoid users)

— RLS is chronic, manageable, not a degenerative disease

— Iron status matters: explain rationale for ferritin >100 target

— Medications to avoid (give written list)

— Trigger management (caffeine, alcohol, nicotine, sleep deprivation, prolonged sitting)

— Realistic expectations: medications reduce, not eliminate symptoms in many patients

— Augmentation warning signs if on dopamine agonist — patient should report immediately

— ICD warning signs — instruct patient and family member to monitor

— Driving safety on dopamine agonists (sleep attack risk)

— Sleep hygiene checklist

— Exercise log

— Compression/vibration device use

Initial follow-up cadence:

Ongoing follow-up:

Monitoring parameters at each visit:

Counseling points to document:

Non-pharmacologic adherence:

Board pearl: Document the conversation about impulse control disorders before initiating any dopamine agonist — this is both standard of care and medicolegal protection.

Step 3 management: Use shared decision-making tools and validated severity scores to track response over time — boards favor data-driven titration over symptom anecdote.

Ethical, Legal, and Patient Safety Considerations

— Patients must be explicitly informed of augmentation and impulse control disorder risks before prescribing pramipexole, ropinirole, or rotigotine

— Document discussion of pathological gambling, hypersexuality, compulsive shopping, binge eating, and punding

— Provide written information; offer to involve a family member

— Lawsuits have been successful when ICD warnings were inadequate — this is a documented medicolegal exposure

— Counsel patients on dopamine agonists about sleep attacks and daytime somnolence

— Discuss avoiding driving when initiating or titrating

— In states with reporting laws for impaired drivers (CA, OR, others), be aware of obligations

— Required: opioid use agreement, PDMP query, naloxone co-prescription (CDC 2022 guideline), urine drug screen at baseline and periodically

— Avoid concurrent benzodiazepines; if unavoidable, document risk discussion

— Co-existing OSA increases opioid respiratory risk — screen and treat

— Hospital admissions are high-risk for severe RLS exacerbation: missed home doses, new metoclopramide/antipsychotics, prolonged bedrest

— At discharge: medication reconciliation must verify home RLS regimen resumed

— At admission: flag RLS in problem list; provide rotigotine patch if NPO

— RLS is underdiagnosed in minority and lower-income populations

— IV iron access varies by insurance — advocate for prior authorizations when oral iron fails

— Shared decision-making with caregivers; consider fetal/lactation effects in every medication choice

— Avoid dopamine agonists in pregnancy/lactation

— Maintain accurate "medications to avoid" list visible in EHR

— Reconcile with every new prescriber, especially psychiatry, oncology (antiemetics), GI (prokinetics)

— Severe RLS can qualify for ADA accommodations (flexible scheduling, breaks)

— Document functional impact in chart for patients seeking accommodation

Informed consent for dopamine agonists:

Driving safety:

Opioid prescribing safety:

Transitions of care risks:

Health equity considerations:

Pediatric and pregnant patients:

Pharmacy and primary care communication:

Disability and workplace accommodation:

Board pearl: A patient develops severe pathological gambling 18 months into pramipexole therapy — physician failed to warn or screen. The legal and ethical standard is documented pre-prescription informed consent and periodic screening.

Step 3 management: At every dopamine agonist refill, ask explicitly about ICD behaviors and document the response.

High-Yield Associations and Rapid-Fire Clinical Facts

URGE mnemonic — diagnostic criteria all five required

Ferritin target >100 ng/mL, TSAT >20% — treat iron in RLS even with normal Hgb if ferritin <75

α2δ ligands (gabapentin enacarbil, pregabalin) = first-line for chronic-persistent RLS per current AAN/AASM

Dopamine agonists (pramipexole, ropinirole, rotigotine) — effective but limited by augmentation and impulse control disorders

Augmentation features: earlier onset, increased intensity, anatomic spread, shorter benefit duration — do not increase dose

Impulse control disorders in 14–17% of dopamine agonist users: gambling, hypersexuality, shopping, eating

Rotigotine patch — useful for 24-hr symptoms, NPO patients, ESRD; lower augmentation rate

Gabapentin enacarbil 600 mg at 5 PM — FDA-approved specifically for RLS

Secondary causes (mnemonic IRON-P): Iron deficiency, Renal failure (ESRD), Offending meds, Neuropathy, Pregnancy

Worsening medications: SSRIs, SNRIs, TCAs, mirtazapine, diphenhydramine, metoclopramide, prochlorperazine, antipsychotics

Bupropion = antidepressant of choice in RLS (does not worsen)

Pregnancy RLS: 20% prevalence, peaks 3rd trimester, treat with iron/folate, avoid dopamine agonists

ESRD RLS: 20–30% prevalence; optimize iron, dialysis, anemia; rotigotine patch favored

PLMS in 80% of RLS but not required for diagnosis

PSG not required for routine RLS diagnosis

Carbidopa-levodopa daily → very high augmentation rate, avoid as chronic therapy

IV iron of choice = ferric carboxymaltose (watch for hypophosphatemia)

Familial primary RLS — 50% have positive family history; BTBD9, MEIS1 genes

Comorbid depression risk doubled; comorbid hypertension and possibly CVD

Walking relieves RLS vs rest relieves PAD — the cardinal differentiator

Akathisia = drug-induced, no circadian pattern, whole body, not RLS

Children with RLS often misdiagnosed as ADHD or growing pains; check ferritin

Refractory RLS → α2δ + dopamine agonist + low-dose opioid (methadone, oxycodone ER)

Board pearl: The single highest-yield action in any new RLS workup is checking ferritin and repleting iron — it is both diagnostic insight and disease-modifying therapy.

Board Question Stem Patterns

— 45-yo woman, months of trouble falling asleep, "creepy crawly" in legs at night, relieved by walking, family history. Exam normal. Next step?

— Answer: Check ferritin (not PSG, not start dopamine agonist immediately)

— Premenopausal woman with heavy menses, new RLS, Hgb 11.8, ferritin 28. Next step?

— Answer: Oral iron repletion (every other day with vitamin C), reassess in 3 months

— Patient on pramipexole 0.5 mg for 2 years now has symptoms starting at 2 PM, spreading to arms. Next step?

— Answer: Recognize augmentation, do not increase dose; check ferritin, switch to α2δ ligand or rotigotine patch

— Patient on ropinirole develops new gambling debts. Most appropriate action?

— Answer: Taper and discontinue ropinirole, transition to alternative therapy

— Patient with stable RLS started on sertraline by psychiatry now with marked worsening. Best step?

— Answer: Switch antidepressant to bupropion

— Hospitalized patient on haloperidol for delirium with restless leg movement throughout day, no circadian pattern. Diagnosis?

— Answer: Akathisia; reduce antipsychotic, consider propranolol

— 3rd-trimester woman with new severe RLS. First step?

— Answer: Iron and folate supplementation, non-pharm measures; avoid dopamine agonists

— Older smoker with leg discomfort relieved by rest and worsened by walking. Test?

— Answer: Ankle-brachial index — this is claudication, not RLS

— Dialysis patient with refractory RLS on optimized dialysis. Best first-line agent?

— Answer: Rotigotine patch or appropriately renally-dosed α2δ; address iron

— Child labeled ADHD with leg discomfort and sleep disruption, ferritin 22. Action?

— Answer: Iron supplementation first

Stem 1 — The classic diagnosis:

Stem 2 — Iron deficiency unmasked:

Stem 3 — Augmentation:

Stem 4 — Impulse control disorder:

Stem 5 — Drug-induced exacerbation:

Stem 6 — Akathisia vs RLS:

Stem 7 — Pregnancy:

Stem 8 — PAD differential:

Stem 9 — ESRD:

Stem 10 — Pediatric:

Board pearl: Most RLS questions hinge on ferritin checking, augmentation recognition, ICD screening, drug-induced exacerbation, or the PAD/akathisia differential. Master these five patterns.

One-Line Recap

Restless legs syndrome is a clinical diagnosis defined by the URGE criteria, evaluated with a mandatory ferritin (treat if <75, target >100), and managed with iron repletion plus α2δ ligands as first-line — reserving dopamine agonists due to augmentation and impulse-control disorder risks.

Diagnosis: URGE criteria (Urge to move, Rest worsens, Gets better with movement, Evening predominance, not Explained by another condition) — clinical only, no PSG needed routinely.

Workup: Ferritin, TSAT, CBC, BMP, TSH, B12, glucose; replete iron to ferritin >100 — disease-modifying in 30–50%.

Therapy ladder: Non-pharm + remove offending drugs (diphenhydramine, SSRIs, metoclopramide, antipsychotics) → α2δ ligand (gabapentin enacarbil, pregabalin) → dopamine agonist (pramipexole, ropinirole, rotigotine) with augmentation/ICD counseling → opioid for refractory cases.

Special populations: Pregnancy — iron and folate, avoid dopamine agonists; ESRD — rotigotine patch and renally-dosed α2δ; elderly — fall risk and cognitive caution; pediatrics — check ferritin before labeling as ADHD.

Pitfalls to avoid: Increasing dopamine agonist dose for augmentation, missing ICD screening, ordering PSG for classic RLS, prescribing diphenhydramine for sleep in an RLS patient, failing to substitute bupropion when an antidepressant is needed.

Step 3 management: Schedule 4–6 week follow-up after any new therapy, screen for augmentation and impulse control disorders at every dopamine agonist visit, maintain a written "medications to avoid" list in the EHR, and recheck ferritin every 6–12 months.